{"id":338,"date":"2020-07-06T06:41:38","date_gmt":"2020-07-06T06:41:38","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=338"},"modified":"2020-07-06T06:41:38","modified_gmt":"2020-07-06T06:41:38","slug":"01-july-2020-favipiravir-66-7day-7-clinical-improvement-rate-53-7-78-0","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/01-july-2020-favipiravir-66-7day-7-clinical-improvement-rate-53-7-78-0\/","title":{"rendered":"(01 July 2020) Favipiravir-  66.7%,Day-7 clinical improvement rate [53.7\u201378.0%]"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Real-world Experience with Favipiravir for Treatment of COVID-19 in Thailand: Results from a Multi-center Observational Study<\/p>\n<p class=\"\">https:\/\/doi.org\/10.1101\/2020.06.24.20133249<\/p>\n<p class=\"\">Among 247 COVID-19 patients, 63 (23.0%) received \u22651 dose of favipiravir. Of these, 27.0% required an O2\u2212nasal cannula, 9.5% required non\u2212invasive ventilation and\/or high\u2212flow O2\u2212therapy, and 6.4% required invasive mechanical ventilation and\/or ECMO. The median baseline NEWS2 score was 5(0\u221216). The Day\u22127 clinical improvement rate [95%CI] was 66.7%[53.7\u221278.0%] in all patients, 92.5%[75.7%\u221299.1%] in patients who did not require O2\u2212supplementation, and 47.2%[0.4%\u221264.5%] in patients who required O2\u2212supplementation. No life-threatening adverse events were identified. The 28-day mortality rate was 4.8%. Multivariate analysis revealed three poor prognostic factors for Day\u22127 clinical improvement [odds ratio (95%CI); p\u2212value]: older age [0.94 (0.89 to 0.99); p=0.04], higher baseline NEWS2 score [0.64 (0.47 to 0.88); p=0.006], and lower favipiravir loading dose (\u226445 mg\/kg\/day) [0.04 (0.005 to 0.4); p=0.006]. Study reports the promising effectiveness of favipiravir for treating COVID\u221219 patients. In addition to older age and a high baseline NEWS2 score, a low loading dose of favipiravir (\u226545 mg\/kg\/day) was also identified as a poor prognostic factor for early clinical improvement.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Real-world Experience with Favipiravir for Treatment of COVID-19 in Thailand: Results from a Multi-center Observational Study https:\/\/doi.org\/10.1101\/2020.06.24.20133249 Among 247 COVID-19 patients, 63 (23.0%) received \u22651 dose of favipiravir. Of these, 27.0% required an O2\u2212nasal cannula, 9.5% required non\u2212invasive ventilation and\/or&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/01-july-2020-favipiravir-66-7day-7-clinical-improvement-rate-53-7-78-0\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(01 July 2020) Favipiravir-  66.7%,Day-7 clinical improvement rate [53.7\u201378.0%]&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,11],"tags":[26],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/338"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=338"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/338\/revisions"}],"predecessor-version":[{"id":339,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/338\/revisions\/339"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}